New drug combined with brain radiation and spinal fluid chemotherapy for advanced lung cancer

This trial is testing whether Furmonertinib—a targeted drug that works against specific lung cancer mutations—combined with chemotherapy delivered directly into the spinal fluid and focused radiation beams to the brain can help people newly diagnosed with advanced lung cancer that has spread to both the brain tissue and the protective lining around the brain and spinal cord. Researchers are studying whether this three-part approach can improve survival and control the disease better than current treatments.

When lung cancer spreads to the brain—especially to both the brain tissue and the lining around it—patients have very few good treatment options and face poor outcomes. Recent advances with targeted drugs have helped many lung cancer patients live longer, but the cancer often spreads to the brain anyway, which is hard to treat. This trial is exploring whether combining this new medication with chemotherapy and radiation specifically targets brain metastases more effectively.